TOP > 外国特許検索 > ANTIVIRAL AGENT, ABZYME, PRIMER SET, METHOD FOR PRODUCING POLYNUCLEOTIDE, AND METHOD FOR PRODUCING POLYPEPTIDE

ANTIVIRAL AGENT, ABZYME, PRIMER SET, METHOD FOR PRODUCING POLYNUCLEOTIDE, AND METHOD FOR PRODUCING POLYPEPTIDE

外国特許コード F110005297
整理番号 AF12-05WO
掲載日 2011年8月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP053752
国際公開番号 WO 2011102517
国際出願日 平成23年2月21日(2011.2.21)
国際公開日 平成23年8月25日(2011.8.25)
優先権データ
  • 特願2010-034998 (2010.2.19) JP
  • 特願2010-035021 (2010.2.19) JP
  • 特願2010-092461 (2010.4.13) JP
発明の名称 (英語) ANTIVIRAL AGENT, ABZYME, PRIMER SET, METHOD FOR PRODUCING POLYNUCLEOTIDE, AND METHOD FOR PRODUCING POLYPEPTIDE
発明の概要(英語) Disclosed are: an antiviral agent which comprises a novel human antibody κ light chain; a humanized abzyme which is a novel human antibody κ light chain; a polynucleotide, a vector and a transformant, each associated with the human antibody κ light chain; a primer set for efficiently obtaining a human antibody κ light chain that has a function as an antiviral agent or an abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each using the primer set.
従来技術、競合技術の概要(英語) BACKGROUND ART
The present inventors have, heretofore, various of the inventive antibody to an enzyme has been studies were performed to determine (for example, see Patent Document 1). Conventional, fully human antibodies with the enzyme sequence, obtained from multiple myeloma patients (BJP) other than bence-jones protein could not be obtained. Reduced the number of patients with multiple myeloma patients, and has less BJP enzyme activity, human-type antibody was difficult to acquire an enzyme. However, the enzyme is a human antibody, fewer side effects upon administration to a human body is expected to be of the order, and the like and overseas pharmaceutical company, a human antibody is a useful enzyme in the awaited to be developed.
However, rabies is, in developing countries is still large loads infection and disease, if the death rate of the onset of lethal disease in 100%. For rabies, at the present time, in the prevention of the onset of rabies virus in addition to the administration of the vaccine after exposure, no effective therapy. Therefore, the development of treatments for from a new viewpoint is demanded.
In addition, the influenza virus is, from the multiplicity of antigenic, outbreak and often over a wide range, devastating. Therefore, this is similar to the above from the development of treatments for a new viewpoint is demanded.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • UDA, Taizo
  • HIFUMI, Emi
  • NISHIZONO, Akira
  • ARAKAWA, Mitsue
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
参考情報 (研究プロジェクト等) CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close